Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab Monotherapy and in Combination With Pembrolizumab in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer
NCT05117242Phase 2Terminated
- Sponsor
- Genmab
- Start
- Oct 2021
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2 trial of acasunlimab, sponsored by Genmab. Started Oct 2021; status: terminated.
02
Drugs
acasunlimab
Beyond the preview
Go deeper on NCT05117242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117242.